BioMarin Pharmaceutical Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Companies must accurately report major deals; corrections show what changed from original filing.
More shares available for employee compensation affects how ownership gets diluted over time.
Quarterly earnings show if the company is making money and growing its business.
Completed acquisition shows BioMarin paid specific price; investors see deal execution details.
Acquisition closed; BioMarin now owns Amicus and its products, changing company size.
Trial stopping means product development setback; less revenue potential from that treatment.
Major deal announcement signals BioMarin's growth strategy and use of cash.
Stocky reads BioMarin Pharmaceutical Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
BioMarin Pharmaceutical Inc.'s most recent tracked filing was a 8-K/A on 13 Jul 2026: Amended filing corrects April 27 Amicus acquisition disclosure.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.